Trial Profile
Single dose pharmacokinetics of a novel hepatitis C protease inhibitor, SCH 503034, in an oral capsule formulation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2008
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Schering-Plough
- 08 Dec 2008 New trial record.